Randomised Phase 2 Study (JADE) of the HBV Capsid Assembly Modulator JNJ-56136379 with or Without a Nucleos(t)ide Analogue in Patients with Chronic Hepatitis B Infection
Overview
Authors
Affiliations
Objective: We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: NCT03361956).
Design: 232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75 mg (part 1) or 250 mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)-capsid assembly modulator, one time per day or placebo with nucleos(t)ide analogue (NA) (tenofovir disoproxil fumarate/entecavir) or JNJ-56136379 alone (NCT-only) for ≥24 and ≤48 weeks.
Results: In patients who are NCT hepatitis B e-antigen (HBeAg) positive, JNJ-56136379 75 mg+NA and 250 mg+NA showed limited mean (SE) hepatitis B surface antigen (HBsAg) declines (0.14 (0.10) and 0.41 (0.15), respectively) from baseline at Week 24 (primary endpoint; placebo+NA: 0.25 (0.11) log international unit (IU)/mL).In patients who are NCT HBeAg positive, mean (SE) HBV DNA declines at Week 24 were 5.53 (0.23) and 5.88 (0.34) for JNJ-56136379 75 mg+NA and 250 mg+NA, respectively, versus 5.21 (0.42) log IU/mL for placebo+NA. In NCT patients, mean (SE) HBV RNA declines were 2.96 (0.23) and 3.15 (0.33) versus 1.33 (0.32) log copies/mL, respectively.Patients with HBsAg declines had HBeAg and hepatitis B core-related antigen (HBcrAg) declines and some early on-treatment isolated alanine aminotransferase flares. Viral breakthrough occurred with JNJ-56136379 monotherapy with the emerging resistant-variant T33N, but not with JNJ-56136379+NA. JNJ-56136379 treatment beyond Week 24 had a generally small additional effect on viral markers.No study treatment-related serious adverse events or clinically significant changes in laboratory parameters occurred.
Conclusions: In patients with non-cirrhotic CHB, JNJ-56136379+NA showed pronounced reductions in HBV DNA and HBV RNA, limited HBsAg or HBeAg declines in patients who are NCT HBeAg positive, and was well tolerated, but no clear benefit with regards to efficacy of JNJ-56136379 over NA was observed.
Opportunities and challenges for hepatitis B cure.
Roca Suarez A, Zoulim F eGastroenterology. 2025; 1(2):e100021.
PMID: 39944004 PMC: 11731071. DOI: 10.1136/egastro-2023-100021.
Hepatitis B virus infection and its treatment in Eastern Ethiopia.
Kanda T, Sasaki-Tanaka R, Tsuchiya A, Terai S World J Hepatol. 2025; 17(1):99209.
PMID: 39871910 PMC: 11736472. DOI: 10.4254/wjh.v17.i1.99209.
Pharmacophore modeling and QSAR analysis of anti-HBV flavonols.
Baei B, Askari P, Askari F, Kiani S, Mohebbi A PLoS One. 2025; 20(1):e0316765.
PMID: 39804828 PMC: 11730388. DOI: 10.1371/journal.pone.0316765.
New Insights on Hepatitis B Virus Viral Transcription in Single Hepatocytes.
Peng B, Pan L, Li W Viruses. 2025; 16(12.
PMID: 39772138 PMC: 11680359. DOI: 10.3390/v16121828.
Current and emerging strategies for the prevention of hepatocellular carcinoma.
Yeo Y, Abdelmalek M, Khan S, Moylan C, Rodriquez L, Villanueva A Nat Rev Gastroenterol Hepatol. 2024; 22(3):173-190.
PMID: 39653784 DOI: 10.1038/s41575-024-01021-z.